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Abstract 
Background: Circular RNAs (circRNAs) are a new class of RNAs with medical significance. Compared to that 
of linear mRNA transcripts, the stability of circRNAs against degradation owing to their circular structure is 
considered advantageous for their use as biomarkers. As systematic studies on the stability of circRNAs 
depending on the RNA integrity, determined as RNA integrity number (RIN), in clinical tissue samples are 
lacking, we have investigated this aspect in the present study under model and clinical conditions. 
Methods: Total RNA isolated from kidney cancer tissue and cell lines (A-498 and HEK-293) with different RIN 
after thermal degradation was used in model experiments. Further, RNA isolated from kidney cancer and 
prostate cancer tissue collected under routine surgical conditions, representing clinical samples with RIN 
ranging from 2 to 9, were examined. Quantitative real-time reverse-transcription polymerase chain reaction 
(RT-qPCR) analysis of several circRNAs (circEGLN3, circRHOBTB3, circCSNK1G3, circRNA4, and circRNA9), their 
corresponding linear counterparts, tissue-specific reference genes, and three microRNAs (as controls) was 
performed. The quantification cycles were converted into relative quantities and normalized to the expression 
of specific reference genes for the corresponding tissue. The effect of RIN on the expression of different RNA 
entities was determined using linear regression analysis, and clinical samples were classified into two groups 
based on RIN greater or lesser than 6. 
Results: The results of model experiments and clinical sample analyses showed that all relative circRNA 
expression gradually decreased with reduction in RIN values. The adverse effect of RIN was partially 
compensated after normalizing the data and limiting the samples to only those with RIN values > 6. 
Conclusions: Our results suggested that circRNAs are not stable in clinical tissue samples, but are subjected 
to degradative processes similar to mRNAs. This has not been investigated extensively in circRNA expression 
studies, and hence must be considered in future for obtaining reliable circRNA expression data. This can be 
achieved by applying the principles commonly used in mRNA expression studies. 










Circular RNAs (circRNAs) are a new class of 
non-coding RNAs. These RNAs are single-stranded 
and have a covalently closed circular structure lacking 
both the 5'-cap and the characteristic 3′-poly(A) tail of 
linear RNA [1, 2]. Although identified in the 1970s [3], 
they were considered trash elements without any 
actual biological function until 2010. Owing to the 
widespread application of advanced sequencing 
technologies and the advancements in bioinformatics, 
circRNAs are now known to be ubiquitously 
expressed and highly conserved cellular components 
[1, 2, 4, 5]. Several studies have shown that circRNAs 
play important roles in the maintenance of 
endogenous homeostasis. In contrast, many diseases, 
especially cancers, are frequently accompanied by 
altered circRNA expression profiles in the affected 
tissues and body fluids [6-9]. Thus, circRNAs are of 
particular interest as both diagnostic, prognostic, and 
predictive biomarkers, as well as therapeutic target 
structures [6, 7, 10, 11]. 
Meaningful prospective studies have to be 
performed to translate these initial promising findings 
of circRNA biomarker research into clinical practice 
[12]. This requires specifying the pre-analytical and 
analytical requirements for reliable determination of 
circRNA expression. The challenges in this respect 
have been discussed in several reports [1, 13, 14]. In a 
previous study, we have discussed the various 
analytical problems and the necessary methodological 
approaches for the identification, validation, and 
quantification of circRNAs [12]. 
In addition to high-throughput sequencing, 
hybridization, and microarray approaches used for 
the detection circRNAs and expression profiling in 
samples, quantitative real-time reverse-transcription 
polymerase chain reaction (RT-qPCR) is an 
indispensable tool for circRNA research. This 
approach is essential for validation of circRNAs that 
have been identified in genome-wide screening using 
sequencing or microarray technology [4, 15, 16]. 
Furthermore, RT-qPCR can be used for quantifying 
the expression of single circRNAs conveniently when 
their validity as a biomarker has to be assessed in 
clinical studies [7]. However, RT-qPCR is error-prone 
owing to variations in the quality of the RNA used, in 
particular the integrity of the total RNA samples 
under investigation [17-19]. Unfavorable sample 
collection procedures under clinical conditions are a 
common pre-analytical explanation for the 
degradation of isolated total RNA [20]. For mRNAs, 
numerous studies have confirmed that an RNA 
integrity number (RIN) of <5 is indicative of total 
RNA degradation, which is associated with reduction 
in relative mRNA quantities [17-19, 21]. This is much 
less true for miRNAs owing to their short length of 
20−22 nucleotides [17, 22]. Studies have shown that 
the normalization of mRNA expression data of 
degraded total RNA samples to reference genes may 
partially compensate for this detrimental effect of 
RNA integrity on expression analysis [17-19, 23]. 
Many studies have emphasized the advantage of 
using circRNAs as biomarkers owing to their stability 
[1, 7, 24, 25]. Little is known to date about the in vivo 
degradation of circRNAs [26]. The intracellular 
stability of circRNAs is due to their unique circular 
structure, which renders them resistant to 
exonucleases such as RNase R [27]. This does not 
consider though the homeostasis of the complex RNA 
degradation pathways, which can be perturbed 
during the collection of clinical tissue samples before 
they are stored under stabilizing conditions [28, 29]. 
This might also change the potential degrading 
activity of endonucleases on total RNA under these 
conditions. Some studies have noted potential 
difficulties in quantifying circRNAs in degraded total 
RNA samples [7, 13, 30, 31]. Therefore, it is surprising 
that the majority of recent circRNA expression-related 
studies in cancer tissues have ignored the possible 
influence of RIN on the measured values (Table S1). 
Studies in peripheral blood samples considered this 
effect [32-35]. Overall, systematic studies on 
circRNAs, similar to those mentioned above for 
mRNAs, are lacking, although they are necessary. In 
the following, the term stability is exclusively used to 
characterize the relationship between the expression 
values of circRNAs or mRNAs measured by RT-qPCR 
and the RNA integrity of the test samples. 
Therefore, the aims of this study were to 
investigate (a) how RNA integrity, as a pre-analytical 
factor, affects the RT-qPCR results of circRNAs, (b) 
whether the stability of circRNAs differs from those of 
their linear counterparts, tissue-specific reference 
genes, and miRNAs, and (c) whether the adverse 
effects of poor total RNA integrity on the RT-qPCR 
results of circRNAs can be corrected or reduced by 
normalizing with the expression of reference genes. 
Toward these objectives, we first performed model 
experiments, in which we determined the expression 
of different RNA species in artificially degraded total 
RNA samples isolated from two cell lines and a 
kidney cancer tissue pool. Subsequently, we 
addressed the clinical situation by determining 
RIN-dependent expression of different RNAs in total 
RNA isolated from kidney and prostate cancer tissue 
specimens. In clinical tissue samples, we examined 
three circRNAs (Table 1) that are annotated in the 
database circBAse as hsa_circ_0101692, hsa_circ_ 
0001522, and hsa_circ_0007444 [36]. The first two are 





validated circRNAs in the kidney or prostate; the 
third was detected in both organs [37, 38]. 
Furthermore, the linear transcripts of the host genes of 
the circRNAs were measured. In the following, the 
terms circEGLN3, circCSNK1G3, and circRHOBTB3 for 
the circRNAs and linEGLN3, linCSNK1G3, and 
linRHOBTB3 for the linear counterparts are used in 
reference to the corresponding host genes to facilitate 
the presentation of comparisons (Table 1). 
Materials and Methods 
Tissue specimens and cell lines 
Tissue samples were obtained from patients with 
clear cell renal cell carcinoma (ccRCC) and prostate 
cancer (PCa) undergoing radical nephrectomy and 
radical prostatectomy, respectively. The Ethics 
Committee of the Charité - University Medicine, 
Berlin, approved the study (EA1/135/12) and 
informed consent was obtained from all patients. The 
study was performed in accordance with the 
Declaration of Helsinki. The clinicopathological 
characteristics of the patients are summarized in 
Tables S2 and S3. The samples were randomly 
selected from our RNA isolation bank, but were 
limited by RNA amount and the completeness of 
patient data. Tissue samples were snap-frozen in 
liquid nitrogen immediately after surgery and stored 
at −80 °C or transferred into the RNAlater 
stabilization reagent (Qiagen, Hilden, Germany) and 
stored at −20 °C until RNA isolation as described 
previously [39, 40]. The human cell lines A-498 (ATCC 
no. HTB-44; established from human kidney 
carcinoma) and HEK-293 (ATCC CRL-1573; 
established from human embryonic kidney) were 
cultured under standard conditions and harvested at 
80−90% confluence. 
Extraction and quality control of total RNA 
Total RNA, including miRNAs, was isolated 
using the miRNeasy mini kit (Qiagen) as described 
previously [22, 39-41]. Briefly, approximately 50 mg 
tissue or 1 × 106 cells were disrupted in 700 µL Qiazol 
in a TissueLyser (Qiagen) at 30 Hz for 2 × 1 min. The 
homogenate was processed according to the 
manufacturer's instructions, with the inclusion of an 
on-column DNase digestion step. RNA was eluted 
from the spin column membrane with 30 µL 
nuclease-free water. RNA yield and purity were 
controlled by measuring the absorbance on the 
NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA). The median 
RNA concentrations in the tested clinical samples 
were 1086 (95% CI: 996 to 1172) ng/µL from kidney 
cancer and 957 (95% CI: 846 to 1031) ng/µL from 
prostate cancer. The ratio of the absorbance at 260 nm 
and 280 nm of all isolated RNA samples ranged from 
1.89 to 2.01. The RIN was assessed on a Bioanalyzer 
2100 with the Agilent RNA 6000 Nano Chip Kit 
(Agilent Technologies, Santa Clara, CA, USA; Cat. No. 
5067-1511). Isolated RNA samples were stored at −80 
°C until analysis. Further details are listed in the 
checklist (Table S4) of the Minimum Information for 
Publication of Quantitative Real-Time PCR (MIQE) 
guidelines [42]. 
In vitro RNA thermal degradation experiments 
After preliminary experiments on artificial heat 
degradation of total RNA samples, an experimental 
design was developed. This should take into account 
all influencing variables and allow measurement of all 
RNA variables under equal conditions for a 
representative experiment with matched samples 
(Figure 1 and 2). Therefore, RNA pools were prepared 
using total RNA samples isolated from three separate 
cell culture experiments and eight different ccRCC 
tissue samples. The RNA extracts were adjusted to 
equal concentrations of 650 ng/µL. The pools were 
prepared by mixing equal volumes of the individual 
RNA samples to maximally compensate for 
variabilities in individual expression. Ten microliters 
of the described RNA pools from cell lines and tissue 
samples were incubated in microcentrifuge tubes at 80 
°C for 90 min in a thermal block cycler (Biometra 
GmbH, Göttingen, Germany) as described previously 
[22]. The degradation was stopped by transferring the 
tubes to an ice bath. The samples were stored at -80 °C 
until analysis (one RIN determination with Agilent 




Figure 1. Decrease in RNA integrity after time-dependent thermal degradation of 
total RNA isolated from renal cell lines A-498 and HEK-293, and the kidney cancer 
tissue pool. The RNA samples were incubated at 80 °C in Eppendorf tubes for 
different time points and subsequently transferred to an ice-bath to stop the 
degradation and stored at -80 °C until analysis. The RIN values at the time points 
were for the A-498 cells: 10.0, 9.0, 8.2, 7.1, 6.1, 4.4, 3.3, and 2.7; for the HEK-293 
cells: 9.7, 8.3, 7.1, 5.8, 4.9, 3.7, 2.8, and 1.9 (the last sample was excluded in further 
analysis); and for the tissue pool: 8.2, 7.9, 7.0, 6.6, 5.8, 4.6, 3.6, and 3.0. The gel like 
view of total RNA samples after heat degradation analyzed with the total Agilent RNA 
6000 Nano Chip Kit on the Agilent 2100 bioanalyzer is shown in Figure S1. 





Table 1. List of circRNAs and their linear mRNA counterparts in this study 
RNA name in the manuscript a References in circBase b or NCBI Genbank c Official gene symbol of the host gene and its full name 
circEGLN3 hsa_circ_0101692 EGLN3, egl-9 family hypoxia inducible factor 3 
linEGLN3 NM_022073.4 
circRHOBTB3 hsa_circ_0007444 RHOBTB3, Rho related BTB domain containing 3 
linRHOBTB3 NM_014899.4 
circCSNK1G3 hsa_circ_0001522 CSNK1G3, casein kinase 1 gamma 3 
linCSNK1G3 NM_001044723.2 
circRNA4 d hsa_circ_0001900 CAMSAP1, calmodulin regulated spectrin associated protein 1 
circRNA9 d hsa_circ_0001423 AFF1, AF4/FMR2 family member 1 
a: In the text, the abbreviated names of the circRNAs (circ+host gene symbol) and mRNAs (lin+host gene symbol) are used to facilitate the readability of the text. 
b: Database circBase, http://www.circbase.org [36]. 
c: Genbank of National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/. 
d: According to Memczak et al [4]. 
 
RT-qPCR measurements of circRNAs, 
mRNAs, and miRNAs 
The quantification characteristics are listed in the 
checklist of the MIQE guidelines as mentioned above 
(Table S4). Detailed validation results of circEGLN3 
and circRHOBTB3, based on the general 
characteristics of circRNAs regarding their resistance 
to the RNase R digestion, their lack of a poly(A) tail, 
the amplification results in complementary DNA 
(cDNA) and genomic DNA (gDNA) using divergent 
and convergent primers, and the proof of the 
backsplice junctions by Sanger sequencing, are 
compiled in our previous report on circRNAs in 
kidney cancer [37]. For circCSNK1G3 measurements, 
the reaction conditions described in the recently 
published circRNA landscape of prostate cancer were 
used [38]. The analytical specificity of the RT-qPCR 
products of these circRNAs were verified by melting 
curve analysis and gel electrophoresis (Figure S2). 
cDNA synthesis 
Maxima First Strand cDNA Synthesis Kit for 
RT-qPCR (Thermo Fisher Scientific, Waltham, MA, 
USA) including a ready-to-use mix of random 
hexamer and oligo(dT)18 primers was used for 
circRNAs and mRNAs in final reaction volume of 20 
µL with 1 µg total RNA [37] (Table S5A). To address 
the issue of reliability of reverse transcription, we 
additionally used another cDNA synthesis kit 
(Transcriptor First Strand cDNA Synthesis Kit, Life 
Science Roche, Mannheim, Germany; Cat. No. 
04379012001) that allows a separate priming with 
either random hexamer or oligo(dT)18 primers (Table 
S5B). The qPCR results for circEGLN3, circRHOBTB3, 
and circCSNK1G3 in kidney and prostate tissue 
pooled samples clearly showed a marked decreased 
expression in all circRNAs when using oligo(dT)18 
primers compared with hexamer primers (Figure S3). 
These data also prove that the circRNAs have no 
poly(A) tails and we can safely assume that the 
transcription primer mix does not impair the 
expression results obtained for circRNAs. On the 
other hand, by using a primer mix, we can ensure a 
maximal reverse transcription in the degraded 
samples for messenger RNAs that ensures that we do 
not impair the impact of degradation on these 
molecules. 
Reverse transcription of miRNAs was performed 
with the TaqMan microRNA reverse transcription kit 
(Thermo Fisher Scientific, Applied Biosystems, Foster 
City, CA, USA) using miRNA-specific stem-looped 
primers according to the manufacturer’s instructions, 
which is described in Supplementary Material, as well 
as in our previous reports [22, 39-41]. 
Quantification 
qPCR measurements were performed on the 
LightCycler 480 (Roche Molecular Diagnostics, 
Mannheim, Germany) using white 96-well plates 
(Roche) in a reaction volume of 10 µL. 40 cycles were 
used as described previously [37]. Reaction 
conditions, measurement details, and performance 
data for the circRNAs circEGLN3, circRHOBTB3, and 
circCSNK1G3, and their linear mRNA counterparts, 
the control circRNAs circRNA4 and circRNA9 
according to Memczak et al. [4], the reference genes 
encoding peptidylprolyl isomerase A (PPIA) and 
TATA-box binding protein (TBP) for ccRCC samples 
[43], 5'-aminolevulinate synthase 1 (ALAS1) and 
hypoxanthine phosphoribosyltransferase 1 (HPRT1) 
for PCa samples [44], and the three miRNAs, let-7a-5p, 
miR-17-5p, and miR-210-3p are summarized in 
Supplementary Material Tables S6–S10. No-template 
and no-reverse transcription controls were always 
performed and showed negative results. All cDNA 
samples were measured at least in duplicate, and the 
mean values of the quantification cycles (Cq) were 
used for calculations. To minimize analytical variation 
in the degradation experiments, samples of an 
experiment were run, as far as possible, in one plate. 
The repeatability of the measurements of all analytes 
showed variation in percentage relative standard 
deviations (%RSD) below 9% (Table S11). In 





measurements of clinical samples, run controls were 
used on each plate. Reproducibility of the inter-assay 
measurements revealed %RSD values between 7.88 
and 13.8% (Table S11). 
Data analysis, statistics, and sample size 
calculation 
Expression changes with respect to the 
corresponding starting points due to RNA 
degradation were calculated using the 2-ΔCq method. 
The percentage changes in expression among 
experiments could be compared as equal amounts of 
total RNA were used in the RT-qPCR analyses. 
QBase+ software version 3.2 (Biogazelle, Zwijnaarde, 
Belgium; www.qbaseplus.com), which is based on a 
generalized model of the 2-ΔΔCq approach with 
correction of amplification efficiency, was used for 
data evaluation [45, 46]. In this program, Cq values 
were converted into relative quantities (RQs) with 
respect to the amount of total RNA (equal for all 
samples) used for the cDNA synthesis, and into 
normalized relative quantities (NRQs) based on the 
expression of two cancer-specific reference genes in 
patient samples as mentioned above. 
GraphPad Prism 8.4.2 for Windows (GraphPad 
Software, San Diego, CA, USA) and MedCalc 19.2.0 
(MedCalc Software bvba, 8400 Ostend, Belgium) were 
used for statistical analyses. Mann-Whitney U-test, 
Wilcoxon test, linear regression analysis, and matched 
analysis of variance (ANOVA) were performed as 
indicated in the Results. The significance of the slope 
was determined based on its deviation from zero and 
the differences between slopes. Sample size and 
power calculations to assess the effect of RIN on the 
expression of circRNAs, their linear counterparts, and 
reference genes in clinical tissue samples were 
performed using the MedCalc software. The 
calculation was based on comparing the mean change 
in the expression in two sample groups with lower (≤ 
6) and higher (> 6) RIN. An effect size (difference of 1 
standard deviation between the mean values of the 
groups with equivalent sample numbers) was 
considered when power was 0.9 and P < 0.05. 
Twenty-two samples were used to assess the effect of 
RIN under these conditions. Hence, at least 25 
samples of every RIN group were included in this 
study. P-values < 0.05 (two-sided) were considered 
statistically significant. 
Results 
Expression of circRNAs, mRNAs, and miRNAs 
in total RNA degraded in vitro 
In vitro degradation of isolated total RNA samples 
To investigate the expression of circRNAs, 
mRNAs, and miRNAs in total RNA samples as a 
function of RNA integrity, the RNA samples were 
artificially degraded by heating. The kinetics of 
time-dependent RIN reduction as an indicator of 
changes in RNA integrity is shown in Figure 1 for 
RNA samples isolated from the cell lines A-498 and 
HEK-293, as well from the ccRCC tissue pool. An 
exponential one-phase decay equation describes the 
effect of heat-degradation on the corresponding 
decreased RIN values as a function of time. This is 
characterized by the half-life: 24 min for A-498 cells 
and 17 min for HEK-293 cells. For the tissue pool, a 
value of 34.6 min was calculated since the initial value 
was already lower in comparison to the initial RIN 
values of RNA samples from the cell lines. However, a 
systematic comparison of the "decay curves" was not 
performed because the method of heat-degradation 
was only used to obtain samples of artificially 
degraded total RNA. 
RT-qPCR using in vitro degraded RNA sample 
RT-qPCR showed that the relative expression of 
individual RNAs after thermal treatment-mediated 
degradation was different from that before heating of 
the total RNA samples (Figure 2A-C). Collectively, 
these differences depended on the integrity of the 
RNA samples (reflected in the RIN), the source of the 
isolated total RNA (two cell lines and ccRCC tissue 
pool), the type of RNA (circRNAs, mRNAs, and 
miRNAs), and the individual RNAs of each RNA 
family. With the exception of microRNAs, which 
showed stable expression irrespective of the RNA 
integrity of the test samples, the expression of all 
individual circRNAs and mRNAs decreased with 
reduction in RIN. The degradation experiment with 
their dependent samples (RIN differences; different 
RNA variables) was evaluated with corresponding 
matched ANOVA calculations. The effect of the RNA 
integrity on the expression level of the RNA variables 
and also the effect between the various variables were 
statistically significant (P = 0.0055 to <0.0001). The 
extent of reduction in expression differed between 
individual circRNAs and mRNAs. For example, RNA 
integrity affected the expression of TBP mRNA and 
circEGLN3 more than that of the PPIA mRNA and 
circRHOBTB3, respectively (Figure 2A and 2C). 
Furthermore, the differences in expression between 
circRNAs and their linear counterparts (e.g., 
circRHOBTB3 vs. linRHOBTB3) became more evident 
in total RNA samples with reduced RIN. This effect 
partially differed depending on the source from 
which the total RNA was isolated. 
 
 






Figure 2. Expression of circRNAs, mRNAs, and miRNAs depending on RNA 
degradation in renal cell lines A-498 and HEK-293, and the kidney cancer tissue pool. 
In the RNA samples shown in Figure 1 with their RNA integrity number (RIN) listed 
in its legend, all RNA variables (including the conventional reference genes PPIA and 
TBP for mRNA expression studies in kidney cancer) were analyzed using RT-qPCR 
and converted to relative values, which are depicted as percentage mean values of 
triplicates with respect to the starting RIN (RIN 10 for A-498, 9.7 for HEK-293, and 
8.2 for kidney cancer tissue pool). In order not to impair the clarity of the figure with 
the various curves, no error bars were drawn in. The analytical variations of the 
intra-plate measurements for the RNA variables in the degradation experiments 
correspond to the %RSD values of the repeatability data in Table S11 (<9%). Linear 
regression lines were calculated for miRNAs with slopes that did not differ 
significantly from zero (P-values between 0.157 and 0.877) and with intercepts 
between 94% and 107% with 95% confidence intervals, while always including the 
starting point of 100%. CircRNA4 and circRNA9 were included in this study as controls 
to confirm the effect of RNA integrity on established circRNAs used in other studies 
[4]. Abbreviations: PPIA: peptidylprolyl isomerase A; TBP: tata-box binding protein. 
 
Reference genes as normalizers in degraded RNA 
samples 
We investigated whether the decrease in the 
expression of circRNAs and their respective linear 
transcripts in the degraded RNA samples could be 
compensated by normalization in order to obtain 
initial expression data before the degradation of the 
RNA samples. For this purpose, all expression data of 
the other RNA variables were normalized to the mean 
expression levels of TBP and PPIA at the respective 
RIN values. TBP and PPIA are exemplarily used here 
as validated reference genes for ccRCC expression 
studies [43]. This approach is in agreement with the 
recommendations for using at least two reference 
genes for normalization [45-47]. Figure 3A-C shows 
that the percentage changes in the expression of the 
four circRNAs and the two linear RNAs linEGLN3 
and linRHOBTB3 after normalization to the initial 
expression values prior to degradation depended on 
the RIN of the degraded RNA samples. The 
percentage deviations in the expression of the 
degraded samples were clearly lower than the 
decrease in expression shown in Figure 2 due to this 
normalization approach. For example, the comparison 
of the percentage expression at RIN 6 in Figures 2 and 
3 with the starting values before degradation showed 
that the median percentage after normalization of all 
six RNA variables (circRNA4, circRNA9, circEGLN3, 
circRHOBTB3, linEGLN3, and linRHOBTB3) in the 
three RNA sources amounted to 95.5% (95% CI, 88.7% 
to 103%), while the median percentage without this 
adjustment was only 65.5% (95% CI, 58 to 69.3%; n = 
18, Wilcoxon test, P < 0.0001). These results support 
the view that errors due to the use of degraded RNA 
samples can be partially compensated via adjustment 
with a combination of suitable reference genes. On the 
other hand, over- and undercorrections of different 
RNAs beyond the here selected limit of 15% are 
observed in dependence on the RIN value of samples 
(Figure 3A-C). Miscorrection can occur if a different 
degradation pattern exists between the normalization 
approach and the target RNA. Thus, an additional 
specification of the RIN value up to which samples 
should be analyzed for reliable results would help to 
avoid this error. As recently outlined, this should be 
part of a multiphase process to develop circRNA 
assays for clinical practice [12]. 






Figure 3. Expression of circRNAs and their linear counterparts depending on RNA 
degradation in renal cell lines A-498 and HEK-293, and the kidney cancer tissue pool 
after normalization to the reference genes PPIA and TBP. The percentage results refer 
to the expression data used in Figure 2, but normalized to the reference genes PPIA 
and TBP using the qbase+ software. Abbreviations: PPIA: peptidylprolyl isomerase A; 
TBP: tata-box binding protein. 
Expression of circRNAs and mRNAs in kidney 
and prostate cancer depends on RNA integrity 
To counter the argument that the model 
experiments with thermally degraded RNA samples 
do not reflect the processes that influence RNA 
integrity during sample collection, storage, and 
processing, we analyzed the expression changes in 
tissue samples with varying RIN values due to 
sampling conditions. We used RNA isolated from 
kidney cancer samples and assessed the expression 
levels of the previously mentioned circRNAs and 
their linear counterparts, including those of the 
reference genes PPIA and TBP. In addition, we used 
prostate cancer samples and included circCSNK1G3. A 
circRNA deregulated in PCa [38] and the established 
mRNA normalizers ALAS1 and HPRT1 for PCa 
expression studies [44] in our assay panel. As RIN 
values between 5 to 7 have been recommended as 
suitable integrity criteria [17-19, 21], we used the RIN 
value of 6 as cutoff to obtain two groups with 
approximately similar number of patients. According 
to the sample size calculation described in Materials 
and Methods, we analyzed 61 ccRCC tissue samples, 
28 with RIN ≤ 6 and 33 with RIN > 6, and 57 PCa 
tissue samples, 26 with RIN ≤ 6 and 31 with RIN > 6 
(Figure 4). The clinicopathological characteristics of 
the two RIN-related patient groups (Tables S2 and S3) 
did not differ significantly (P-values from 0.150 to 
1.000; except for the age of patients with PCa). Thus, 
the contribution of the clinicopathological factors to 
possible expression differences in the two RIN groups 
may be ignored. Expression of all circRNAs and 
mRNAs calculated as relative quantities in both 
kidney and prostate cancer patients were significantly 
lower in RNA samples with RIN values ≤ 6 than in 
those with RIN values > 6 (Figure 4A-B). In contrast, 
using the normalization approach with two 
conventional reference genes for the respective cancer 
type, the expression of most circRNAs and their linear 
counterparts were found not to differ between the two 
RIN groups in both cancers, except circEGLN3 and 
linEGLN3, which were found to differ in ccRCC 
samples even after normalization (Figure 4A-B). Even 
if RIN 7 was selected as cutoff, the differences 
remained (Table S12). The normalization of all 
circRNAs and linear transcripts (NRQ) did however 
result in significantly lower slopes in the linear 
regression analysis in contrast to the slopes obtained 
when analyzing the relative quantities (RQ) (Figure 5 
with detailed statistics in Tables S13 and S14). 
Furthermore, none of the slopes of measured RNA 
differed significantly from zero when analyzing only 
the ccRCC samples with RIN values > 6 (Figure 5; 
P-values from 0.169 to 0.771 with detailed statistics in 





the Table S13). In prostate cancer samples with RIN > 
6, the slopes of the linear regression equations of all 
normalized RNAs did not differ from zero, but 
differed significantly when the relative quantities of 
linCSNK1G3, circRHOBTB3, and linRHOBTB3 were 
analyzed (Table S14). Collectively, the adverse effect 
of RIN can be only partially compensated by 
adjusting the expression data of the target RNAs to 
those of suitable reference genes, although this was 
dependent on the RNA variables, tissue source, 
reference genes, and RIN of the RNA samples. As 
explained above at the example of the model 
experiment, miscorrection may specifically occur 
when reference genes and the target RNAs have 
different degradation patterns. 
 
 
Figure 4. Differential expression of circRNAs and their linear counterparts in kidney and prostate cancer tissue samples with RIN values of < 6 and > 6 and calculated as relative 
quantities and normalized relative quantities. The expression data of RNA samples isolated from (A) clear cell renal cell carcinoma with RIN < 6 (n = 28; median 4.3, range 
2.3−6.0) and > 6 (n = 33; median 7.7, range 6.1−9.4) and from (B) prostate cancer with RIN < 6 (n = 26; median 3.5, range 2.2−5.5) and > 6 (n = 31; median 7.4, range 6.3−8.2). 
Data are shown as box- and whisker plots with the individual values of samples. Boxes represent the lower and upper quartiles with medians; whiskers illustrate the range from 
the minimum to the maximum value. Expression levels are presented as relative quantities (RQs) and normalized quantities (NRQs) using the software qbase+ as described in 
Materials and Methods. Statistical significance was tested using the Mann-Whitney U-test. 






Figure 5. Regression analysis of the expression of circRNAs and their linear counterparts in (A) kidney and (B) prostate cancer tissue samples depending on RIN and their 
quantification as relative quantities and normalized relative quantities. Linear regression line analyses of the expression levels presented as relative quantities (RQs) and 
normalized relative quantities (NRQs) in Figure 4 were performed. Data were calculated both for samples over the whole range of RIN and only for samples with RIN > 6. 
Statistical differences between the slopes of RQs and NRQs, and their deviation from zero were assessed. The results have been summarized in the Tables S13 and S14 and have 
been described in Results. 
 
Discussion 
It is well acknowledged that the integrity of the 
starting RNA material is one of the decisive factors for 
obtaining reliable gene expression data using 
RT-qPCR. It is therefore of particular practical 
importance to analyze the adverse effects of RNA 
degradation on circRNA expression levels in clinical 
tissue samples. This concerns both the RNA samples 
isolated from fresh tissue samples, either immediately 
frozen or preserved in RNA storage solution, as well 
as from formalin-fixed paraffin-embedded (FFPE) 
tissue, the most routinely preserved tissue material 
for diagnostic purposes [42]. The quality of the total 
RNA isolated from clinical samples may be affected 
by the delayed processing interval between the 





acquisition and stabilized storage of samples [48]. As 
a result, the ongoing endogenous RNase activities 
lead to the degradation of the total RNA. In the case of 
FFPE samples, the fixation process causes additional 
degradation. However, RNA integrity may also be 
compromised by the sample transport, handling of 
the samples, and the purity of the reagents and tubes 
used for the RNA isolation or by storage [20]. Thus, 
estimation of the extent of degradation of the starting 
RNA sample is a fundamental prerequisite for reliable 
downstream RT-qPCR measurements, which is 
specified in the MIQE guidelines [42]. As briefly 
stated in the Introduction, the extent of degradation of 
the starting material can be assessed using the RIN 
obtained from microfluidics-based RNA analysis 
(Agilent) or the RNA quality indicator (Bio-Rad), or 
using different RT-qPCR-based tests such as the 3':5' 
ratio assay or 5':3' ratio assay, and an assay based on 
testing of different amplicons [17, 18, 20, 49-52]. 
In this study, we determined the integrity of all 
total RNA samples using RIN as the most frequently 
used integrity indicator of total RNA, which is also 
comprehensible for a broad scientific community. To 
focus our investigations on the effect of RNA integrity 
on expression analysis, other interfering factors of 
RT-qPCR, such as primer design, cDNA synthesis, 
and adjustments for PCR efficiency were avoided [18, 
45, 46, 53]. This was also necessary, as additional 
comparative analyses of the circRNAs with the 
corresponding linear transcripts of their host genes 
had to be accomplished. Therefore, PCR primers were 
designed for short amplicons < 250 bp independent of 
RNA integrity [18, 54]. A mixture of random and 
oligo(dT) primers was used for efficient cDNA 
synthesis for all measurements [53], an additional 
reverse transcription experiment with separate 
random hexamer and oligo(dT)18 primers was 
performed for circRNA validation (Figure S3), and 
PCR efficiency-adjusted expression was calculated 
using the qbase+ algorithm [45, 46]. Furthermore, the 
in vitro model experiments were performed with 
thermally degraded total RNA isolated from two cell 
lines and a kidney cancer tissue pool. This approach 
has been applied in other studies [19, 55]. 
Comparative studies on different artificial 
degradative processes for total RNA have shown that 
thermal degradation changes RNA integrity in a 
manner that mimics that of degradation by ubiquitous 
RNases [49, 52, 56]. 
After carefully considering these analytical 
requirements and the acceptable limits of data 
repeatability and reproducibility, we concluded that 
the integrity of total RNA samples significantly affects 
the accuracy of the RT-qPCR read-outs for circRNA 
expression analysis. To the best of our knowledge, 
this is the first systematic study on the effect of RNA 
integrity on RT-qPCR analysis of circRNAs compared 
to that of mRNAs. The results of the model studies on 
artificially degraded total RNA samples (Figures 
2A-C and 3A-C) and those on clinical samples with 
different RIN values (Figures 4A, B and 5A, B) 
indicated that circRNA expression analysis is affected 
in a manner similar to those of mRNAs in degraded 
RNA samples. This clearly contrasts the robustness of 
miRNA expression (let-7a-5p and miR-17-5p) under 
adverse RNA integrity conditions shown in this study 
(Figure 2), which is in agreement with previous 
observations [17, 22]. Apart from these general 
observations regarding the effect of RNA integrity, 
difference in expression was observed between 
individual circRNAs (for example, circEGLN3 vs. 
circRHOBTB3; Figure 2A) and between circRNAs and 
their corresponding linear transcripts (for example, 
circRHOBTB3 vs. linRHOBTB3, Figure 2C). The 
intracellular stability of circRNAs was considered 
advantageous for their use as biomarkers [1, 7, 24-26]. 
However, the total RNA undergoes degradation by 
different endonucleases as soon as a tissue is removed 
from the body, which is active at different pH values 
and prefer different substrates [57]. As a result, the 
expression of circRNAs is altered in a manner similar 
to that of mRNAs if the sample is not stabilized 
immediately. An overview of 25 randomly selected 
circRNA tissue expression studies in different cancers 
published between 2015 and 2020 (Table S1) revealed 
that the RNA integrity was mostly not reported and 
has not been considered so far as possible adverse 
effect on circRNA measurements. However, per 
MIQE guidelines [42], this is the basic requirement for 
generating robust data for biomarker studies and 
clinical decision-making in future. 
Furthermore, these results indicated that the 
evaluation of circRNA expression in clinical tissue 
samples is associated with the same problems as with 
the measurement of mRNA expression: (a) can 
measurements of circRNAs in degraded RNA 
samples be corrected to the (probable) initial value 
and (b) is there a critical limit of RNA integrity that 
should not be crossed for obtaining reliable results? 
As circRNA and mRNA expression decrease similarly 
with reduction in RIN (Figure 2A-C), the percentage 
changes from the initial value are significantly smaller 
when mRNA expression is used for normalization, 
which was TBP and PPIA in our model study (Figure 
3). This approach corresponds to the procedure that is 
now generally used for the normalization of mRNA in 
RNA samples degraded via different ways [17-19, 23]. 
The more is the similarity in the degradation profiles 
of target and reference RNAs, the smaller is the 
deviation of the corrected value of the degraded 





sample from the expected value of the intact sample 
[23]. An alternative, particularly for practical reasons, 
is the combination of several reference genes with 
different degradation profiles into a RIN-based 
algorithm that should be used for all circRNA 
measurements in a study. For example, Cheung et al. 
[19] developed a special RIN-based corrective 
algorithm with nine reference genes for estimating 
mRNA levels in degraded RNA samples. 
Furthermore, RIN 5–7 was recommended as the lower 
limit for obtaining reliable mRNA and miRNA 
expression data using RT-qPCR [17, 18, 58, 59]. 
However, from a practical point of view, it is 
advisable to combine the correction-based and 
limit-based assessment, as has been done in this 
study. This is also highlighted by the finding that 
even the normalization was not able to sufficiently 
harmonize the apparent differences of circEGLN3 and 
linEGLN3 in ccRCC samples. Thus, based on our 
results (Figures 4 and 5), we would suggest a RIN 
value of six as the limit and the use of at least two 
specific reference genes, PPIA and TBP, for kidney 
cancer samples or ALAS1 and HPRT1 for prostate 
cancer samples [43, 44]. Under these conditions, 
satisfactorily bias-corrected circRNA expression data 
can be obtained in the model experiments (Figure 3) 
and for our clinical samples (Figures 4 and 5). We 
believe that this approach is suitable for obtaining 
meaningful circRNA expression data for a "fit-for- 
purpose" procedure applicable in future clinical 
studies [60]. 
As already emphasized above, it is not 
surprising that the generally accepted procedures for 
normalizing RT-qPCR measurements have received 
little attention in circRNA expression studies so far 
[17, 18, 42, 45, 46]. For example, the "obsolete" 
housekeeping genes ACTB and GAPDH are used 
frequently as single normalizers (Table S1). 
Furthermore, normalization with at least two 
validated reference genes, a long-established 
approach in mRNA expression studies [47], is rarely 
applied (Table S1). In this respect, improvements 
should also be made for future circRNA studies. 
Zhong et al. [61] recently recommended the use of 
hsa_circ_0000284 and hsa_circ_0000471 as generally 
applicable reference genes in all circRNA expression 
studies. The authors only examined the stability of 
circRNAs with regard to their resistance to RNase R 
digestion. However, the suitability of these circRNAs 
as stable expressed normalizers in expression studies 
and also their degradation pattern in relation to the 
RNA integrity need further detailed investigations. 
Our study has some limitations. First, only few 
circRNAs and only two carcinoma types were 
analyzed. However, the general and differential 
degradation behavior of individual circRNAs, and 
their dependence on the tissue under investigation are 
already evident. In addition, the strict adherence of 
the investigation to the MIQE guidelines, the 
robustness of the analytical performance data, the 
calculated sample size (α = 0.05; β = 0.10) that 
excludes type I and II errors as far as possible, and the 
comparable clinicopathological characteristics of the 
two different RIN groups support the general validity 
of the measured and evaluated data. Second, our 
results of circRNA measurements refer only to the 
RT-qPCR methodology and did not consider the 
particularities of other analytical techniques like 
microarray, hybridization methods, RNAseq, and 
next generation sequencing. Irrespective of the 
situation with other methods, it is necessary to 
consider this issue for RT-qPCR measurements of 
clinical samples. Moreover, the specific problem of 
FFPE material needs clarification [31, 62-64]. New 
RNA quality metrics, which are more sensitive than 
the RIN values generally used up to now, are 
recommended to define the preanalytical RNA 
conditions for reliable expression analyses in future 
studies [63, 64]. These are, for example, the DV 200 
that represents the percentage of RNA fragments 
longer than 200 nucleotides or the Q-score that 
characterizes the ratio of the GAPDH amplicons of 165 
bp to 80 bp. A multiphase development process is 
necessary for the introduction of new circRNA-based 
assays into clinical practice [12]. After the 
identification and validation of a circRNA, clinical 
validation must be performed. This requires robust 
assays of RT-qPCR measurements. All decisive 
parameters of the pre-analytical phase (sample 
collection, processing, storage conditions), the 
analytical phase (RNA isolation protocols, analytical 
inclusion/exclusion criteria of samples for further 
analysis, quantification principles with performance 
data) and the post-analytical phase (data evaluation 
and normalization approach) must be defined. 
In summary, this is the first systematic study 
comparing the stability of circRNAs with those of 
their linear mRNA transcripts from the same host 
gene in clinical tissue samples. CircRNAs showed 
similar degradation profiles as mRNAs in isolated 
total RNA samples. The degradation behavior 
differed between individual circRNAs and was 
tissue-specific. Based on RNA integrity as the 
indicator of RNA degradation, the RT-qPCR read-outs 
of circRNAs were found to be affected similar to those 
of mRNAs. This has not been sufficiently considered 
in previous studies on circRNA expression. Based on 
the observations of RT-qPCR analysis of mRNAs, we 
concluded that the adverse RNA integrity effect can 
be partly compensated in an appropriate manner if (a) 





tissue-specific reference genes are used as normalizers 
that are validated and recommended in their number 
by normalization software like geNorm in the 
software package qbase+ (corrective-based approach) 
[45, 46] and (b) if only RNA samples within a certain 
integrity limit (limit-based approach; in the present 
study: RIN > 6) are selected as appropriate study 
samples. Such a combined approach, adapted always 
on the objectives of the respective study, allows the 
exclusion of pre-analytically unsuitable samples and 
provides measurement results applicable for clinical 
practice. This is the prerequisite for exploiting the full 
potential of circRNAs as diagnostic, prognostic, and 
predictive biomarkers in future circRNA tissue 
expression studies [12]. 
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